Halaman 1 dari 45 hasil
Chemotherapy can affect taste and smell function. This may contribute to the high prevalence of overweight and metabolic syndrome in testicular cancer survivors (TCS). Aims of the study were to evaluate taste and smell function and possible consequences for dietary intake, food preference, and body
OBJECTIVE
Cisplatin based combination therapy is curative in most patients with advanced testicular cancer. Previous reports have suggested that hypercholesterolemia is a common complication in this patient group. We performed a cross-sectional study to assess further the relationship of cisplatin
OBJECTIVE
To assess cardiovascular risk factors over time in patients who received chemotherapy for disseminated testicular cancer and were apparently cured.
METHODS
Cohort study.
METHODS
Referral center.
METHODS
Fifty-seven consecutive patients (median age, 28 years; range, 16 to 43 years) who
The present study aimed at exploring the relations between body mass index (BMI) and stature and testicular cancer in a huge Norwegian cohort with measured height and weight. Height and weight were measured in 600,000 Norwegian men aged 14-44 years during 1963-2001. Results from parts of the study
Results of CT and US examinations in 24 patients with testicular tumors yielded similar sensitivity and specificity in the diagnosis of enlarged retroperitoneal lymph nodes found at laparatomy. Therefore, the choice of either imaging modality may be influenced by other factors such as presence of
BACKGROUND
Traditionally, the incidence of testicular cancer (TCa) has shown a remarkable geographical variation.
OBJECTIVE
To examine whether the rates of TCa varied within Ireland itself and to find possible explanations for any observations made.
METHODS
We observed the incidence of TCa in
BACKGROUND
Studies assessing the relationships of anthropometry and testicular germ-cell tumour (TGCT) have reported heterogeneous findings.
METHODS
We undertook a systematic review and meta-analysis of the associations between adult height, weight, body mass index (BMI), and testicular cancer.
Although a rare tumor, testicular cancer shows substantial international variation in incidence. In whites, the peak incidence occurs at 25-30 years of age, with a second increase in old age. Blacks have much lower rates than do whites. The rate of increase in the incidence and mortality of this
Testicular cancer survivors treated with chemotherapy are at increased risk for metabolic syndrome (MetS) and cardiovascular disease (CVD). We explored acute effects of chemotherapy by assessing metabolic factors, abdominal fat volume, hepatic triglyceride content (HTC) and aortic wall stiffness.
We
Testicular cancer is diagnosed at a young age and survival rates are high; thus, the long-term effects of cancer treatment need to be assessed. Our objectives are to estimate the incidence rates and determinants of late effects in testicular cancer survivors.
We conducted a population-based cohort
The two patients were males aged over 30 years. To treat testicular tumors, combination chemotherapy with bleomycin, etoposide, and cisplatin (BEP) had been employed. In case 1, during the 4th course of BEP therapy, thoracic pain suddenly appeared. Emergency coronary angiography revealed thrombus
OBJECTIVE
To review and summarize the contemporary knowledge of the implications of obesity on perioperative outcomes in oncological urologic surgeries.
RESULTS
In men undergoing radical prostatectomy, obesity seems to confer a higher risk of intraoperative bleeding, biochemical recurrence, urinary
OBJECTIVE
The current study evaluates the extent and reversibility of late sequelae after chemotherapy in longterm survivors of testicular cancer. The influence of therapy and patient characteristics and the relationship between different toxicities are assessed.
METHODS
Ninety patients with a
BACKGROUND
Cross-sectional studies showed that treatment with cisplatin chemotherapy for testicular cancer is associated with an increased incidence of cardiac dysfunction. We investigated longitudinal progression of and contributing factors to cardiac dysfunction in testicular cancer
Purpose To provide new information on adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) after four cycles of etoposide and cisplatin (EPX4) or three or four cycles of bleomycin, etoposide, cisplatin (BEPX3/BEPX4). Methods Nine hundred fifty-two TCSs > 1 year postchemotherapy